Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN 8 5.
AMINOSYN 5% vs AMINOSYN 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Aminosyn 8.5% is a crystalline amino acid solution that provides a source of nitrogen and essential/non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It serves as a substrate for metabolic pathways, including gluconeogenesis and ketogenesis, and supports immune function and enzyme production.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (11.8-17.6 mL/kg/day of 8.5% solution) via central line; rate not to exceed 0.1 g amino acids/kg/hour.
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Variable; amino acids have rapid distribution and metabolic half-lives of minutes to hours; terminal half-life of infused amino acid mixtures is approximately 1–2 hours for most components in patients with normal hepatic function
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Renal elimination of infused amino acids as urea, ammonia, and other nitrogenous waste products; minimal biliary/fecal excretion (<2%)
Category C
Category C
Amino Acid Solution
Amino Acid Solution